Parkinson's disease (PD) is caused by abnormal accumulation of α-synuclein in
dopaminergic neurons of the substantia nigra, which subsequently causes motor symptoms …

Parkinson's disease (PD) is a progressive neurodegenerative disorder caused mainly by
lack of dopamine in the brain. Dopamine is a neurotransmitter involved in movement …

To date, no reliable clinically applicable biomarker has been established for Parkinson's
disease. Our results indicate that a long anticipated blood test for Parkinson's disease may …

Abstract Objective The Parkinson's Progression Markers Initiative (PPMI) is an
observational, international study designed to establish biomarker‐defined cohorts and …

Abstract Parkinson's disease (PD), the second most common progressive
neurodegenerative disease, develops and progresses for 10–15 years before the clinical …

Parkinson's disease is a neurological disorder with evolving layers of complexity. It has long
been characterised by the classical motor features of parkinsonism associated with Lewy …

We have developed a novel real‐time quaking‐induced conversion RT‐Qu IC‐based assay
to detect alpha‐synuclein aggregation in brain and cerebrospinal fluid from dementia with …

Parkinson's disease (PD) is a progressive neurodegenerative disorder, which is
characterised by degeneration of distinct neuronal populations, including dopaminergic …

The Alzheimer's disease (AD) afflicted brain is neuropathologically defined by extracellular
amyloid-β (Aβ) plaques and intraneuronal neurofibrillary tangles composed of …

The differential diagnosis of Parkinson's diseases (PD) is challenging, especially in the early
stages of the disease. We developed a microRNA profiling strategy for exosomal miRNAs …